Endocrine Abstracts

BXL-628 is a non-hypercalcemic calcitriol analog successfully tested in a phase IIa trial for benign prostate hyperplasia therapy. Because part of low urinary tract symptoms (LUTS) are generated by overactive bladder (OAB) and bladder expresses the calcitriol receptor (VDR), we investigated the BXL-628 effects on bladder contractility and RhoA/ROK signalling activated in OAB, by in vivo (2-weeks; 30 mcg/Kg, Sprague-Dawley, SD, and spontaneously hypertensive rats, SHR) a...

Introduction: It is general acknowledgement that obesity is associated with a systemic, low-grade inflammatory state. Although the relationship between obesity and semen parameters or prostate diseases has been previously investigated, the association between body mass index (BMI), prostate inflammatory diseases and colour-Doppler ultrasound (CDU) features of the male genital tract (MGT) has been poorly studied. This study was aimed at evaluating the association between BMI an...

Introduction: Interleukin 8 (IL8) is a proinflammatory cytokine highly expressed in seminal plasma. Seminal IL8 (sIL8) has been proposed as a reliable surrogate marker of prostatitis and as a potential marker of male accessory gland infection (MAGI). So far, no study systematically evaluated the correlations of sIL8 with colour-Doppler ultrasound (CDU) features of the male genital tract. Hence, we investigated these possible correlations in infertile patients with MAGI.<p ...

Metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) are often associated. One of their common denominators is hypogonadism. However, testosterone supplementation is limited by concerns for potential prostatic side effects. The objective was to determine whether MetS-associated prostate alterations are prevented by testosterone supplementation. We used a previously described animal model of MetS, obtained by feeding male rabbits ...